These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15954422)

  • 1. [Hepatitis B vaccine].
    Kurokohchi K; Kuriyama S
    Nihon Rinsho; 2005 May; 63 Suppl 5():638-42. PubMed ID: 15954422
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B].
    Wang XY; Yao X; Guo LM; Xu LF; Shen XL; Xu DZ; Zhao K; Wen YM
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):718-20. PubMed ID: 19785971
    [No Abstract]   [Full Text] [Related]  

  • 3. [The role of dysfunction of dendritic cells in hepatitis B virus persistent infection].
    Horiike N; Onji M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():70-3. PubMed ID: 15453289
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anti-HBs escape mutants--implication of neutralization escape and diagnostic escape].
    Okamoto H
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():98-105. PubMed ID: 15453295
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of circadian rhythm on the efficacy of the hepatitis B vaccination.
    Karabay O; Temel A; Koker AG; Tokel M; Ceyhan M; Kocoglu E
    Vaccine; 2008 Feb; 26(9):1143-4. PubMed ID: 18255201
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Persistence of immunity after hepatitis B vaccination].
    Madaliński K
    Przegl Epidemiol; 2002; 56(4):605-13. PubMed ID: 12666586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B vaccines: protective efficacy and therapeutic potential.
    Michel ML; Tiollais P
    Pathol Biol (Paris); 2010 Aug; 58(4):288-95. PubMed ID: 20382485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunological tolerance to hepatitis B surface antigen].
    Yamauchi K
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():84-7. PubMed ID: 15453292
    [No Abstract]   [Full Text] [Related]  

  • 10. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
    Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S
    Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
    Li L; Tian YJ; Shen H; Zhao XP; Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B?
    Huo TI; Wu JC
    J Gastroenterol Hepatol; 2004 Aug; 19(8):841-3. PubMed ID: 15242483
    [No Abstract]   [Full Text] [Related]  

  • 13. A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia.
    Ijaz S; Khulan J; Bissett SL; Ferns RB; Nymadawa P; Tedder RS
    J Med Virol; 2006 Dec; 78(12):1554-9. PubMed ID: 17063521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Induction of specific cytotoxic T lymphocyte response against hepatitis B virus by hepatitis B virus S gene-modified dendritic cells].
    Lei CL; Huang CH; Yang Z; Tang XP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):108-10. PubMed ID: 17653306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of viral hepatitis B in early infancy--hepatitis B vaccine (HBVac)].
    Tanabe M; Noguchi H; Tsuzuki K; Minowa S; Tsuyuki M; Tsuji A; Itoh S; Kanoh H; Katoh T; Mizokami M
    Nagoya J Med Sci; 1984 Mar; 46(1-4):49-54. PubMed ID: 6234469
    [No Abstract]   [Full Text] [Related]  

  • 16. [Screening for hepatitis B].
    Krogsgaard K
    Ugeskr Laeger; 2002 Jan; 164(2):159-62. PubMed ID: 11831078
    [No Abstract]   [Full Text] [Related]  

  • 17. [Seroconversion of HBs antigen to anti-HBs].
    Ohkoshi S
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():88-92. PubMed ID: 15453293
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2 + S vaccine recipients. Absence of cross-reactivity of subtypes at a major T cell recognition site.
    Cupps TR; Tibbles J; Hurni WM; Miller WJ; Ellis RW; Milich D; Wetter N
    J Immunol; 1993 Sep; 151(6):3353-60. PubMed ID: 7690803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A boost to hepatitis B vaccine: no need for boosters.
    Aggarwal R
    Natl Med J India; 2005; 18(6):313-4. PubMed ID: 16483032
    [No Abstract]   [Full Text] [Related]  

  • 20. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.